Vir Biotechnology Announces Strategic Steps to Reduce Operat

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology –

–...

Related Keywords

Missouri , United States , San Francisco , California , Portland , Oregon , Switzerland , Bellinzona , Ticino , , Nasdaq , Vir Biotechnology Inc , Exchange Commission , Vir Biotechnology , Marianne De Backer , Chief Executive , Private Securities Litigation Reform Act , Markets ,